Macquarie Group Ltd ownership in S49 / Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

DE ˙ DB ˙ US8684591089

37,80 € ↓ -0,60 (-1,56%)

2026-06-03
DEL PRIS

Security	DE:S49 / Supernus Pharmaceuticals, Inc.
Institution	Macquarie Group Ltd
Latest Disclosed Ownership	2,631,897 shares
Ownership	4.78%

2024-11-01 - Macquarie Group Ltd has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,631,897 shares of Supernus Pharmaceuticals, Inc. (DE:S49). This represents 4.78 percent ownership of the company. In their previous filing dated 2024-02-14 , Macquarie Group Ltd had reported owning 2,737,721 shares, indicating a decrease of -3.87 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-11-01	2024-11-01	13G/A	2,737,721	2,631,897	-3.87	4.78	-4.59
2024-02-14	2024-02-14	13G		2,737,721		5.01

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-02-13	2025-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	0		-100.00	0
2025-11-13	2025-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,531,537	-230,587	-8.35	120,982	38.96	0.1412
2025-08-14	2025-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,762,124	62,457	2.31	87,062	-1.53	0.1068
2025-08-14	2025-03-31	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	2,699,667	70,760	2.69	88,414	-6.99	0.1098
2025-05-15	2025-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,699,667	70,760		88,414		0.0722
2025-02-14	2024-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,628,907	-2,990	-0.11	95,061	15.84	0.1153
2024-11-14	2024-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,631,897	-47,899	-1.79	82,063	14.48	0.0886
2024-08-09	2024-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,679,796	10,800	0.40	71,685	-21.26	0.0822
2024-05-14	2024-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,668,996	-68,720	-2.51	91,039	14.90	0.1033
2024-02-14	2023-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,737,716	-13,140	-0.48	79,230	4.47	0.0915
2023-11-14	2023-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,750,856	247,398	9.88	75,841	0.78	0.0953
2023-10-27	2023-06-30	13F/A-2	SUPERNUS PHARMACEUTICALS	COM	868459108	2,503,458	29,389	1.19	75,254	-16.04	0.0860
2023-10-12	2023-06-30	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	2,503,458	29,389		75,254		0.0756
2023-08-14	2023-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,503,458	29,389		75,254		0.0763
2023-06-01	2023-03-31	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	2,474,069	53,535	2.21	89,636	3.82	0.1065
2023-05-15	2023-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,474,069	53,535		89,636		0.0823
2023-02-21	2022-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,420,534	50,414	2.13	86,340	7.59	0.1020
2022-11-14	2022-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,370,120	32,816	1.40	80,247	18.72	0.0984
2022-08-17	2022-06-30	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	2,337,304	17,354	0.75	67,595	-9.85	0.0759
2022-08-15	2022-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,337,304	17,354		67,595		0.0242
2022-05-16	2022-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,319,950	148,522	6.84	74,981	18.42	0.0570
2022-02-11	2021-12-31	13F	Supernus Pharmaceuticals	COM	868459108	2,171,428	34,357	1.61	63,319	11.10	0.0528
2021-11-12	2021-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,137,071	1,148	0.05	56,995	-13.34	0.0486
2021-08-13	2021-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,135,923	52,205	2.51	65,765	20.55	0.0540
2021-05-14	2021-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,083,718	-127,442	-5.76	54,552	-1.94	0.0771
2021-02-16	2020-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,211,160	160,161	7.81	55,633	30.16	0.0812
2020-11-13	2020-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	2,050,999	179,045	9.56	42,743	-3.86	0.0724
2020-08-11	2020-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	1,871,954	143,690	8.31	44,459	42.99	0.0766
2020-05-15	2020-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	1,728,264	222,444	14.77	31,092	-12.95	0.0639
2020-03-18	2019-12-31	13F/A-2	SUPERNUS PHARMACEUTICALS	COM	868459108	1,505,820	183,442	13.87	35,717	-1.71	0.0510
2020-02-28	2019-12-31	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	1,505,820	0		35,717		0.0516
2020-02-14	2019-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	1,505,820	183,442		35,717		44,821.8081
2019-11-14	2019-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	1,322,378	243,377	22.56	36,339	1.78	0.0609
2019-11-06	2019-06-30	13F/A-2	SUPERNUS PHARMACEUTICALS	COM	868459108	1,079,001	84,846	8.53	35,705	2.50	0.0602
2019-09-24	2019-06-30	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	1,079,001	0		35,705		0.0607
2019-08-14	2019-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	1,079,001	84,846		35,705
2019-05-15	2019-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	994,155	247,111	33.08	34,835	40.37	0.0594
2019-02-15	2018-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	747,044	178,682	31.44	24,817	-13.28	0.0480
2018-11-15	2018-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	568,362	568,362		28,617		0.0466
2019-03-21	2018-06-30	13F/A-1	SUPERNUS PHARMACEUTICALS	COM	868459108	0	-78,795	-100.00	0	-100.00
2018-05-11	2018-03-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	78,795	-23,943	-23.30	3,609	-11.85	0.0066
2018-02-14	2017-12-31	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	102,738	15,550	17.84	4,094	17.37	0.0072
2017-11-08	2017-09-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	87,188	-75,375	-46.37	3,488	-50.21	0.0063
2017-08-14	2017-06-30	13F	SUPERNUS PHARMACEUTICALS	COM	868459108	162,563	2,090	1.30	7,006	39.48	0.0128
2017-05-15	2017-03-31	13F	Supernus Pharmaceuticals	COM	868459108	160,473	-2,260	-1.39	5,023	22.24	0.0091
2017-03-30	2016-12-31	13F/A-1	Supernus Pharmaceuticals	COMMON	868459108	162,733	-77,669	-32.31	4,109	-30.88	0.0079
2017-02-15	2016-12-31	13F	Supernus Pharmaceuticals	COMMON	868459108	162,733			4,109
2016-11-15	2016-09-30	13F	SUPERNUS PHARMACEUTICALS	COMMON	868459108	240,402	94,898	65.22	5,945	100.57	0.0114
2016-09-14	2016-06-30	13F/A-1	SUPERNUS PHARMACEUTICALS	COMMON	868459108	145,504	17,104	13.32	2,964	51.38	0.0058
2016-08-15	2016-06-30	13F	SUPERNUS PHARMACEUTICALS	COMMON	868459108	145,504			2,964
2016-05-16	2016-03-31	13F	SUPERNUS PHARMACEUTICALS	COMMON	868459108	128,400	128,400		1,958		0.0039

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.